📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context The GLP-1…
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context Diabetic kidney…
A phase 2b randomized trial found that cotadutide reduced urinary albumin-to-creatinine ratio versus placebo in type 2 diabetes with chronic kidney disease, a surrogate signal requiring confirmation. PICO summary and expert commentary.
Design and baseline-cohort paper for the phase 3 ESSENCE trial of semaglutide 2.4 mg in biopsy-proven MASH with fibrosis stage 2 or 3; no efficacy outcomes are reported. PICO summary and expert commentary.
A single-centre randomized trial testing an integrated data platform plus dietary management against routine care in 180 adults with type 2 diabetes. PICO summary and expert commentary.
A post hoc analysis of SUSTAIN 6 reports lower odds of new-onset diabetic kidney disease with semaglutide versus placebo in people with type 2 diabetes. PICO summary and expert commentary.
A post hoc analysis of SUSTAIN China examining whether the glycaemic efficacy of once-weekly semaglutide versus sitagliptin in adults with type 2 diabetes varies by baseline characteristics. PICO summary and expert commentary.
A small single-dose pharmacokinetic study found that combining insulin icodec and semaglutide into IcoSema roughly doubled semaglutide peak concentration without changing total exposure of either drug. PICO summary and expert commentary.
A manufacturer-sponsored 28-week RCT used mixed-meal testing to compare how tirzepatide and semaglutide improve glucose control in type 2 diabetes. PICO summary and expert commentary.
A pre-specified FLOW subgroup analysis tests whether baseline SGLT2 inhibitor use modifies semaglutide’s kidney and cardiovascular benefit in type 2 diabetes with CKD. PICO summary and expert commentary.